PALO ALTO, Calif., Dec. 11 /PRNewswire/ -- Roche has announced that Hans-Joachim Bohm, Ph.D., has been appointed president of Roche Palo Alto LLC. As president, Dr. Bohm is responsible for managing a research site focused on early discovery in three of Roche's therapy areas: Virology, Neurosciences and Autoimmunity, Inflammation and Transplantation. He also serves as a member of the Research Management Team, which is responsible for allocating resources, implementing portfolio strategy and approving global initiatives. Bohm succeeds Robert B. Stein, MD, Ph.D., who recently assumed another position within the Roche global organization. Bohm will report to Jonathan Knowles, Ph.D., head of Global Research for Roche.
"I am truly delighted to join Roche Palo Alto. It's an exciting place with outstanding people doing great science. I'm proud to be a member of this team," said Bohm. "Roche's motto is 'We innovate healthcare' Silicon Valley's spirit of innovation certainly helps us innovate in our efforts to discover and develop medicines that will improve the lives of patients."
"Joachim has a broad range of experience in pharmaceuticals and a proven track record of delivering new and innovative compounds into development," said Jonathan Knowles, Ph.D., head of Global Research at Roche. "His scientific expertise and leadership talents will complement that of our current management team and be of great value to our research efforts in Palo Alto."
Bohm's previous position was Director of Safety and Technical Sciences for Roche in Basel, Switzerland. With more than 18 years of international experience in pharmaceutical research and development, Bohm has broad expertise in drug target identification, clinical candidate selection, early clinical development, informatics and management.
Bohm earned undergraduate and graduate degrees in chemistry from the University of Karlsruhe, Germany. He joined Roche Basel in 1996 as head of molecular design and bioinformatics, and since then has held a series of positions within the organization. Prior to Roche, Bohm worked in a variety of companies including Siemens and BASF, was a visiting research scientist at the University of Cambridge, and taught at the University of Karlsruhe and the University of Basel, Switzerland.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. Roche has 1,000 people on its Palo Alto campus, located adjacent to Stanford University in California's Silicon Valley. It is one of six global Roche research centers and is focused on the discovery of new medicines to treat neural, viral, inflammatory and immune disorders and to support organ transplantation. Medicines discovered at Roche Palo Alto include CellCept(R) (mycophenolate mofetil), Valcyte(R) (valganciclovir) and Naprosyn(R) (naproxen). For more information, please access http://paloalto.roche.com.
All trademarks used or mentioned in this release are protected by law.
RocheCONTACT: Ron Fuchs of Roche, +1-650-851-6853
Web site: http://paloalto.roche.com/
